Single Agent Glasdegib Patients Myelofibrosis Previously Treated Ruxolitinib
Single-Agent Glasdegib in Patients with Myelofibrosis Previously Treated with Ruxolitinib
A Phase 2, Double-Blind, Randomized Safety and Efficacy Study of Glasdegib (PF-04449913) versus Placebo in Patients with Myelofibrosis Previously Treated with Ruxolitinib